Abstract Supplementary Information: The online version contains supplementary material available at 10.1038/s41598-025-92844-6. Article type: Research Article Keywords: Cannabis, Maternal, Omega-3…
Abstract Background: Exposure to Δ9-tetrahydrocannabinol (THC) is an established risk factor for later-life neuropsychiatric vulnerability, including mood- and anxiety-related symptoms.…
Abstract Cannabis has shown therapeutic potential in mood and anxiety-related pathologies. However, the two primary constituents of cannabis, cannabidiol (CBD)…
Abstract Despite increased prevalence of maternal cannabis use, little is understood regarding potential long-term effects of prenatal cannabis exposure (PCE)…
Abstract Neurodevelopmental exposure to psychoactive compounds in cannabis, specifically THC, is associated with a variety of long-term psychopathological outcomes. This…
Abstract The rates of gestational cannabis use have increased despite limited evidence for its safety in fetal life. Recent animal…
Abstract Background: Cannabis use in pregnancy leads to fetal growth restriction (FGR), but the long-term effects on cardiac function in…
Abstract Clinical reports of cannabis use prevalence during pregnancy vary widely from 3% to upwards of 35% in North America;…
Abstract 1 in 5 women report cannabis use during pregnancy, with nausea cited as their primary motivation. Studies show that…
Abstract The primary psychoactive compound in cannabis, Δ9-tetrahydrocannabinol (THC), is capable of producing bivalent rewarding and aversive affective states through…